8-(3-Aminopiperidin-1-yl)-7-(2-iodobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione | 454707-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-(3-Aminopiperidin-1-yl)-7-(2-iodobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
• 英文别名: 8-(3-aminopiperidin-1-yl)-7-[(2-iodophenyl)methyl]-1,3-dimethylpurine-2,6-dione
• CAS: 454707-06-3
• 化学式: C₁₉H₂₃IN₆O₂
• 分子量: 494.335
• InChiKey: SQOXLWWIJJBBID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  8-Chloro-7-(2-iodobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione 、 3-氨基哌啶二盐酸盐 生成 8-(3-Aminopiperidin-1-yl)-7-(2-iodobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
  参考文献：
  名称：

  Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states

  摘要：

  本发明涉及一种治疗糖尿病、高血压、慢性心力衰竭和液体潴留状态的方法和组合物，包括向患有上述一种或多种疾病的个体施用NEP和DPP-IV酶抑制剂。抑制这两种酶的活性将增强内源性GLP-1和其他DPP-IV底物（如GIP）的胰岛素释放活性。

  公开号：

  US20030236272A1

文献信息

• Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20030105077A1

  公开（公告）日：2003-06-05

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. 1

  本发明涉及公式I的治疗活性和选择性DPP-IV酶抑制剂，包括该化合物的药物组合物以及利用这些化合物制备用于治疗受DPP-IV失活蛋白质相关的疾病的药物，如2型糖尿病和肥胖症。
• Xanthine derivatives,production and use thereof as medicament
  申请人：——

  公开号：US20040077645A1

  公开（公告）日：2004-04-22

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R4如权利要求1所定义，其互变异构体和立体异构体，混合物，前药和盐具有有价值的药理学性质，特别是对酶二肽基肽酶IV（DPP-IV）的抑制作用。
• Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
  申请人：Himmelsbach Frank

  公开号：US20060205711A1

  公开（公告）日：2006-09-14

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式为的取代黄嘌呤，其中R1至R4如权利要求1所定义的互变异构体和立体异构体，其混合物，以及具有有价值的药理学特性的前药和盐，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。
• Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
  申请人：HIMMELSBACH Frank

  公开号：US20120252782A1

  公开（公告）日：2012-10-04

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are defined as in claim 1 , the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式为的取代黄嘌呤，其中R1至R4的定义如权利要求1所述，其互变异构体和立体异构体，其混合物，以及具有有价值的药理学性质，特别是对酶二肽基肽酶-IV（DPP-IV）活性的抑制作用的前药和盐。
• XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：HIMMELSBACH Frank

  公开号：US20130165428A1

  公开（公告）日：2013-06-27

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are defined as in claim 1 , the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式为的取代黄嘌呤，其中R1至R4如权利要求1所定义，其互变异构体和立体异构体，其混合物，其前药和其盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。